mm: are anti-bcma immunotherapies ready for the frontline?
Published 3 years ago • 34 plays • Length 4:08Download video MP4
Download video MP3
Similar videos
-
2:28
bb21217: next gen anti-bcma car-t for r/r mm
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
1:53
infections following anti-bcma bispecific antibodies for multiple myeloma
-
1:48
mechanisms behind the loss of bcma in multiple myeloma & options for patients
-
4:01
determining the optimal sequencing of anti-bcma therapies in multiple myeloma
-
1:30
managing the challenges associated with continuous bcma-directed therapy in multiple myeloma
-
2:31
integrating bcma-targeted agents in earlier lines of therapy for r/r multiple myeloma
-
11:01
targeting bcma for r/r myeloma
-
13:52
multiple myeloma
-
5:19
what is multiple myeloma?
-
3:19
what is bcma
-
1:45
anti-bcma car t-cell therapy for multiple myeloma: latest studies
-
1:42
first-in-human trial of an anti-bcma adc for r/r myeloma
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
1:32
immunotherapeutics against multiple myeloma: it's all about bcma
-
5:12
anti-bcma lipid-based nanoparticle therapeutic strategy for patients with multiple myeloma
-
0:52
mrd for multiple myeloma: is it ready for prime-time?
-
1:38
using bcma-targeting agents in earlier lines of treatment for multiple myeloma
-
4:27
antibody-based targeting of bcma in multiple myeloma
-
2:23
exciting results from cartitude-1: anti-bcma car-t for mm
-
1:56
bb2121 anti-bcma car t-cell therapy in relapsed/refractory mm
-
3:17
anti-bcma car t-cells for mm: durable clinical responses with bb2121